How non-classical RAS proteins help cancers grow
Regulation and tumorigenesis of non-classical RAS oncoproteins - Resubmission
['FUNDING_R01'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-11238533
This project looks at how lesser-known RAS proteins and their regulation can cause tumors, with the goal of helping people whose cancers involve RAS pathway changes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11238533 on ClinicalTrials.gov |
What this research studies
This team studies non-classical RAS oncoproteins such as RIT1 and MRAS and how they are controlled inside cells. They will examine how a regulator called LZTR1 tags these proteins for degradation and use lab-grown cells, animal models, and human tumor samples to trace the processes. The researchers will use biochemical tests and genetic tools to see how changes in these proteins drive tumor growth. The work aims to pinpoint steps in the pathway that could become targets for new cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates are people with tumors that have mutations or abnormal activity in RIT1, MRAS, or related regulators like LZTR1 who might provide tissue samples or be eligible for future targeted trials.
Not a fit: Patients whose cancers are not driven by RAS pathway changes or who lack RIT1/MRAS/LZTR1 alterations are less likely to benefit directly from this research.
Why it matters
Potential benefit: If successful, the work could uncover new drug targets or biomarkers for cancers driven by non-classical RAS proteins, potentially leading to better, more targeted treatments.
How similar studies have performed: While targeting some classical RAS mutations has recently produced effective drugs, research specifically on non-classical RAS proteins like RIT1 and MRAS is earlier-stage and less proven.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CASTEL, PAU — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: CASTEL, PAU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.